Biosergen AS
BIOSGNStockST
7.60 ▼ 6.17%
12 juin 2026
B
Biosergen AS
7.60 ▼ 6.17%
12 juin 2026
BIOSGNStockST

01 / À propos

Biosergen AB (publ), a biotech company, develops antifungal products. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Arberion
Loading market data